Dr. Hamilton Discusses Tucatinib in HER2+ Breast Cancer

Erika P. Hamilton, MD
Published: Tuesday, Oct 24, 2017



Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

Tucatinib is a tyrosine kinase inhibitor (TKI) that only blocks HER2, sparing patients from some of the adverse effects that come with the neratinib (Nerlynx) and lapatinib (Tykerb). This TKI easily crosses the blood-brain barrier, says Hamilton, so it works well in patients with brain metastases.

Currently, tucatinib is being evaluated in randomized trial with capecitabine and trastuzumab (Herceptin) at Sarah Cannon Research Institute.
 


Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

Tucatinib is a tyrosine kinase inhibitor (TKI) that only blocks HER2, sparing patients from some of the adverse effects that come with the neratinib (Nerlynx) and lapatinib (Tykerb). This TKI easily crosses the blood-brain barrier, says Hamilton, so it works well in patients with brain metastases.

Currently, tucatinib is being evaluated in randomized trial with capecitabine and trastuzumab (Herceptin) at Sarah Cannon Research Institute.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x